Modular Medical shares surge 11.49% after-hours after validating Pivot controller line for Q1 2026 launch, demonstrating manufacturing readiness for high-volume production of its tubeless insulin patch pump.

Modular Medical surged 11.49% in after-hours trading following the announcement of successful validation of its Pivot controller line for human-use production, a key milestone ahead of its Q1 2026 market launch. The validation confirms manufacturing readiness for high-volume production of the Pivot, a tubeless, removable 3-milliliter patch pump targeting the $3 billion "almost-pumper" market segment. The company emphasized the Pivot’s potential to address unmet demand with its affordable, user-friendly design and scalable manufacturing platform. CEO Jeb Besser highlighted the achievement as a critical differentiator in the patch pump space, reinforcing confidence in the product’s commercial viability. The news directly aligns with the stock’s upward movement, as it reduces manufacturing risks and positions Modular Medical to capitalize on a growing diabetes technology market.